Low-Dose Naltrexone Reduces Pain and Improves Function in Fibromyalgia
Results of a systematic review and meta-analysis showed that LDN was safe and effective for reducing pain and improving functional outcomes in fibromyalgia.
Low-dose naltrexone (LDN) significantly reduces pain and improves functional outcomes among patients with fibromyalgia while maintaining a favorable safety profile, according to study results presented at the American College of Rheumatology (ACR) Convergence 2025, held from October 24 to 29, in Chicago, IL.
Fibromyalgia is a chronic pain syndrome characterized by musculoskeletal pain and fatigue, significantly impacting daily function and quality of life.
Current treatment options often provide limited relief, prompting interest in alternative therapies such as LDN — which may act through neuroimmune modulation and enhancement of endogenous opioid activity.
LDN was safe and effective for reducing pain and improving functional outcomes in fibromyalgia.
Author summary: LDN reduces pain in fibromyalgia patients.
More News
- The mentoring methods you need to try
- Thousand Oaks Biologics Showcases Integrated ADC CRDMO Solutions & Media Innovation for Industrialization at CPHI Frankfurt 2025
- GRID Powers Up: XSite Braehead Unveils Bold New Identity
- Glaude urges a simple reponse to MAGA: 'You're lying' – Baptist News Global
- ‘Like It Was Yesterday’: The 1985 Villanova Football Team Reunited For Its 40th Anniversary
- China Bistro Ignites Ealing with Tangra Spice and 50% Off Food
- Elaine Hendrix on Vegan Living, ‘Dancing With the Stars’, and Life After ‘The Parent Trap’
- TSMC's Global Expansion Strategy Accelerates Across Multiple Fronts () | aktiencheck.de
- When Bill Skarsgård's Pennywise Appears in It TV Show Possibly Revealed - Comic Book Movies and Superhero Movie News - SuperHeroHype
- Vietnam Draft AI Law: Regulatory Milestone and Business Implications